In 2022, the Swiss pharmaceutical industry transferred some CHF218 million ($243 million) to doctors, hospitals and other healthcare providers, according to the self-declaration of 65 pharmaceutical companies. Novartis topped the list with CHF31 million.
This content was published on
2 minutes
Keystone-SDA
Português
pt
Indústria farmacêutica suíça pagou CHF 218 milhões a prestadores de serviços de saúde
Since 2015, the industry has been reporting its payments to healthcare providers under its Code of Pharmaceutical Cooperation. Over eight years, the companies have paid a total of CHF1.4 billion to the medical profession and hospitals.
Journalists from the Ringier Axel Springer publishing house evaluated the figures and published them on Thursday. The pharmaceutical association Scienceindustries confirmed the figures to the Keystone-SDA news agency.
Roche came in second place behind Novartis, with CHF21.9 million paid out, followed by the American group Pfizer with CHF20 million.
According to Scienceindustries, the payments are governed by law and authorised for research, continuing education, consultancy and other services. The industry lists the recipients individually and by name.
This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo.ch we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles. You can find them here.
If you want to know more about how we work, have a look here, and if you have feedback on this news story please write to english@swissinfo.ch.
External Content
Your subscription could not be saved. Please try again.
Almost finished… We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.
Popular Stories
More
Life & Aging
Switzerland no longer wants to foot the bill for ‘suicide tourism’
Swiss parliament calls for deeper EU security cooperation
This content was published on
The House of Representatives has called on the Swiss government to take a more proactive approach to European security policy.
Switzerland has no US-style fentanyl problem, says health minister
This content was published on
There is very little chance of a US-sized fentanyl epidemic in Switzerland, says health minister Elisabeth Baume-Schneider.
This content was published on
Two fish species recently discovered in Switzerland have been called fluvicola and ommata, following an appeal to the public for names.
Convicted ex-shipowner achieves partial success in Swiss court
This content was published on
The Federal Supreme Court orders lower court to reassess part of its verdict against former Swiss shipowner Hans-Jürg Grunder.
This content was published on
A Swiss moratorium on the genetic engineering of plants, which expires at the end of 2025, could be extended for five years.
SWISS airline achieves second-best profit in history
This content was published on
Revenues soared for Swiss International Air Lines in 2024, contributing to the second-largest profit in the company's history.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.